Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines.
PLOS ONE | https://doi.org/10.1371/journal.pone.0192068 March 9, 2018
Cette note d'information décrit les nouvelles lignes directrices de l'OMS recommandant que les personnes présentant un stade avancé de la maladie à VIH reçoivent un paquet défini de soins. Celui-ci comprend le dépistage, le traitement et la prévention d’infections opportunistes majeures, a...fin de réduire la morbidité et la mortalité.
more
Translated and adapted from the original English Antiretroviral drugs chart by the East Europe and Central Asia Union of People Living with HIV (ECUO). This resource shows drugs currently available in the Eastern Europe and Central Asia area.
Last update Oct. 2018
The shortage of human resources for health, and in particular physicians, is one of the major barriers to achieve universal access to HIV care and treatment. In September 2005, a pilot program of nurse-centered antiretroviral treatment (ART) prescription was launched in three rural primary health ce...nters in Rwanda. We retrospectively evaluated the feasibility and effectiveness of this task-shifting model using descriptive data.
more
A Systematic Review and Meta-analysis
Clinical Infectious Diseases® 2016;62(12):1586–94
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
This clinical job aid addresses the importance of maternal health and antiretroviral therapy adherence, as well as care and testing for the HIV-exposed infant until the infant’s final HIV diagnosis after the end of breastfeeding.
The following information provides guidance to health care providers attending to the medical needs of HIV-infected adults (including pregnant women) or children displaced from disaster areas who have not yet secured HIV care in the areas where they have relocated.
(*)
- HHS Panel on Antiretrov...iral Guidelines for Adults and Adolescents
- HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
- HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults & Adolescents
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infection in HIV-Infected Children
more
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
Accessed: 26.02.2020
The World Health Organization (WHO) has recommended a universal antiretroviral therapy (ART) for all HIVinfected children before the age of two since 2010, but this implies an early identification of these infants. We described the Prevention of Mother-to-Child HIV Transmission (PMTCT) cascade, the ...staffing and the quality of infrastructures in pediatric HIV care facilities, in Ouagadougou, Burkina Faso.
more
People living with HIV depend on life-saving antiretroviral therapy (ART) and access to ART must be maintained during periods of travel restrictions and lockdowns resulting from the COVID-19 pandemic. The Information note on HIV and COVID-19 addresses common concerns people living with HIV have rega...rding the risks of COVID-19 and how to minimize them. For HIV programme managers and health facilities providing HIV services, it identifies key points related to ensuring uninterrupted provision of ART, while protecting clients and staff from the risk of infection with the SARS-CoV-2 virus.
more
The objective of this report is to assess the situational landscape during mid-May 2020 surrounding the value chain of the production and distribution of generic antiretroviral medicines in low- and-middle-income countries and to provide recommendations on mitigating the risks of potential disruptio...ns.
more
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform A...RT programme decision making regarding optimal ART regimens and support evaluation of programme quality with respect to maximizing viral load suppression and minimizing emergence of resistance in people taking ART.
more
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...stance in adults, children and adolescents receiving dolutegravir-based ART.
This sentinel method is implemented complementary to WHO-recommended methods for estimating nationally representative levels of acquired HIV drug resistance.
more
In 2015 around 15 million people living with HIV were receiving antiretroviral treatment (ART) in sub–Saharan Africa. Sustained provision of ART, though both prudent and necessary, creates substantial long–term fiscal obligations for countries affected by HIV/ AIDS. As donor assistance for healt...h remains constrained, novel financing mechanisms are needed to augment funding domestic sources. We explore how Innovative Financing has been used to co–finance domestic HIV/AIDS responses. Based on analysis of non–health sectors, we identify innovative financing instruments that could be used in the HIV response.
more